相关实验视频

Updated: Jan 9, 2026

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study

Published on: August 18, 2020

测量患者报告结果的试点研究,用于在急诊室治疗的大麻素过度复杂综合征 (CHS) 患者

Ryan Heidish¹, Aditya Loganathan¹, Taylor Bolden¹

¹The George Washington University School of Medicine and Health Sciences, Department of Emergency Medicine, Washington, DC, USA.

Clinical and experimental emergency medicine

|December 2, 2025

概括

参观急诊室 (ED) 的大麻素过度减肥综合征 (CHS) 患者经历了显著的症状和高回归率. 这项试点研究强调了需要进行干预措施,以改善患者报告的结果,并减少CHS的ED复诊.

科学领域:

紧急医疗紧急医疗
胃肠病学胃肠病学
成药物药物药物药物

背景情况:

加拿大大麻类药物过高综合征 (CHS) 是一种导致慢性大麻使用者的反复出现的腹痛和吐的疾病.
腹部疼痛是急诊室 (ED) 访问的主要原因,CHS有助于频繁的呈现.

研究的目的:

评估在试点研究中招募CHS患者的可行性.
在CHS患者中描述患者报告的结果 (PRO).
估计诊断为CHS的患者的30天ED复诊率.

主要方法:

一项前性观察性研究招募了先前有CHS诊断的成年ED患者.
纳入标准要求临床医生判断当前的症状可能是由于CHS.
测量结果包括症状负担,PROMIS-29分数,CT扫描使用,阿片类药物管理和30天的ED回访.

主要成果:

招募了18名参与者 (平均年龄34岁),报告高疼痛严重程度和显著的焦虑.
普罗米斯-29的评分表明,它对日常活动有很大的干扰.
在30天内,16.7%的参与者 (3/18) 回到了ED.

结论:

患有CHS的急诊室患者面临着相当大的症状负担和高的复诊率.
进一步的研究应侧重于改善患者报告结果的干预措施,并减少CHS的ED复诊.

更多相关视频

Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes

Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes

Published on: February 28, 2025

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting

Published on: June 21, 2024

相关概念视频

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...